Search

everythinglearnresearchcommunity

for

Search:↓

A Korean laser helmet increases hair growth by 44% compared to a placebo. Users discuss its cost-effectiveness, clinical support, and compare it to treatments like finasteride and minoxidil, focusing on wavelength and energy density.

Dutasteride at 0.5mg may have fewer sexual side effects than expected, with many side effects attributed to psychological factors (nocebo effect). The placebo group experienced more side effects, suggesting fear and anxiety might contribute to perceived side effects.

High-dose oral minoxidil (>5 mg/day) can increase hair density in some men with androgenetic alopecia, but side effects like extra body hair and heart issues are common. Gradual dose increase is advised, but adverse effects may lead to discontinuation or dose adjustments.

The user has been using finasteride, topical minoxidil, microneedling, red light therapy, ketoconazole shampoo, vitamin supplements, and scalp massages for hair loss since February 2025. They report stronger, thicker hair but are experiencing shedding and are considering increasing finasteride dosage or adding oral minoxidil.

The user experienced hair shedding in late summer after starting finasteride in December 2023, with regrowth by February. They are concerned about shedding again and question if finasteride is losing effectiveness.

The conversation discusses hair loss treatments, specifically the use of RU58841 by individuals who did not respond to dutasteride. Users share experiences with maintaining hair using RU58841 and mention trying pyrilutamide and the upcoming availability of pp405.

The user experienced reduced effectiveness of minoxidil after consistent use, despite using dutasteride to maintain hair. They are considering alternatives like microneedling and exploring options like hair transplants due to dissatisfaction with current hair density.

PP405 is expected to be on the market between 2027 and 2030, with phase 3 trials starting in 2026. There is skepticism about its fast-tracking due to its cosmetic nature, and it may appear on the gray market sooner.

Breezula (clascoterone) Phase 3 hair loss trial results are delayed, with no official updates yet. The acne version is approved, but hair loss results are still pending.

KX-826 (Pyrilutamide) 0.5% and 1.0% solutions showed promising results in increasing hair count for male androgenetic alopecia, with the 0.5% dose slightly outperforming the 1% dose. The treatment was well-tolerated with no sexual side effects, but skepticism remains due to past inconsistencies in trial results.

KX-826 combined with minoxidil significantly increases hair growth compared to minoxidil alone for treating male androgenetic alopecia, with no unexpected safety concerns. Users discuss various hair loss treatments, including KX-826, minoxidil, finasteride, and RU58841, sharing personal experiences and sourcing information.

Cosmo Pharma plans to release Breezula, a hair loss treatment, with expected FDA approval in 2027, but concerns arise over its high potential cost of $225/month. Users express skepticism about its effectiveness compared to cheaper alternatives like finasteride and minoxidil.

The discussion is about whether to continue reducing finasteride dosage with already low DHT levels. Treatments mentioned include minoxidil, finasteride, and RU58841.

Dutasteride tablets are less effective than softgel capsules because they require a fat-based environment for proper absorption. Softgel capsules, like Avodart, are designed to maximize bioavailability, while powdered tablets may result in significantly lower DHT suppression.

PP405 is progressing to Phase 2b trials, with results expected in late 2025 or early 2026, and potential Phase 3 trials in 2026. Some users experienced side effects from finasteride and are hopeful for PP405 as an alternative treatment.

PP405 shows promise as a hair loss treatment, with 31% experiencing increased hair density in a short trial. It may complement treatments like finasteride and minoxidil, but long-term effectiveness and safety need confirmation.

The user is experiencing side effects from Dutasteride 0.5 mg and is considering reducing its frequency or switching back to Finasteride, while continuing with Minoxidil 2.5 mg to preserve their hairline. They are unsure if the increased Minoxidil dose is sufficient for regrowth.

Finasteride is effective in promoting hair growth and reversing hair miniaturization in men with androgenetic alopecia, with improvements seen in various studies over different durations. Some users report initial side effects like ball ache, which often resolve as the body adjusts.

Concerns about France potentially banning finasteride and dutasteride due to supposed side effects, though no solid evidence supports this action. Users believe a ban is unlikely and discuss ways to obtain the treatments if it occurs.

Recruitment for a verteporfin trial and a separate hair cloning trial using verteporfin and other methods is underway, with locations in Jordan, NYC, Beverly Hills, and Memphis. Dr. Bloxham is conducting the hair cloning trial, and interested participants are encouraged to contact him directly.

Microneedling combined with minoxidil is more effective for hair growth than microneedling alone. Optimal results are seen with weekly microneedling using 0.5 - 1mm needles and regular minoxidil application, avoiding minoxidil on the needled area for 24 hours.

Pyrilutamide's long-term stability is uncertain, with potential degradation after 8-9 months if not stored properly. It's recommended to use fresh batches and store them in a cool, dark place.

Oral dutasteride is the most effective for hair regrowth, followed by oral finasteride and minoxidil. Topical finasteride combined with minoxidil is recommended for those avoiding systemic DHT reduction.

Microneedling at depths greater than 0.6 mm may damage miniaturized hair follicles, with 0.5 mm showing better results for hair regrowth. Combining microneedling with minoxidil enhances absorption, but caution is advised to avoid damaging follicles.

Long-term finasteride users often experience periodic hair shedding due to natural hair cycles, even after several years of use. Some consider switching to dutasteride, but concerns about side effects and the effectiveness of finasteride remain common.

A combination of pyrilutamide, minoxidil, and alfatradiol is proposed as an effective alternative to finasteride for treating mild to moderate hair loss, claiming to stabilize hair loss and improve thickness without finasteride's side effects. Some users are skeptical about the effectiveness and approval of these treatments, while others are interested in trying them due to finasteride's side effects.

The user has been using 1.25 mg Finasteride and topical Minoxidil once a day for six months with positive results and no side effects. They emphasize the importance of continuing the medication to maintain hair regrowth and discuss the potential benefits and side effects of different dosages.

Kintor Pharmaceutical's KX-826 shows promising results for hair loss treatment. Users discuss the use of anti-androgens like spironolactone and RU58841, noting concerns about concentration and safety.

The conversation discusses hair thinning potentially linked to creatine use, with the user considering switching from topical to oral finasteride and minoxidil. Creatine may increase DHT levels, but topical treatments are suggested to be effective without significant side effects.

PP405 is expected to finish Phase 2 trials in late 2025, with potential market availability around 2028-2029 if all goes well. Current treatments like finasteride and minoxidil are still popular, while new options like KX-826 and Breezula are anticipated soon.